FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123238480> ?p ?o ?g. }

• W2123238480 endingPage "89" @default.
• W2123238480 startingPage "80" @default.
• W2123238480 abstract "ObjectivesLuteinizing hormone-releasing hormone (LHRH) agonists represent one of the main cost factors in the management of patients with metastatic prostate cancer. We compared the cost-effectiveness of the five different 3-month formulations of LHRH agonists currently available for advanced prostate cancer in Italy, because these differ both in their capacity to suppress testosterone and in their acquisition costs.MethodsA probabilistic, patient-level simulation model was developed to compare the cost-effectiveness, from the perspective of the Italian National Health Service (INHS), of leuprorelin 11.25 mg and 22.5 mg, triptorelin 11.25 mg, buserelin 9.9 mg, and goserelin 10.8 mg. The model incorporated testosterone-dependent progression-free and cancer-specific survival functions, LHRH agonist effectiveness data, and national costs and tariffs. Cox's proportional hazard models were used to compute total and progression-free survival functions based on clinical data from 129 patients with metastatic prostate cancer treated in an Italian center. Bayesian random effects models were employed to summarize evidence from published literature on testosterone suppression obtained with the available LHRH agonists.ResultsEstimated total survival was ≈5 years, with a maximum difference between treatment options of ≈2 months. There was a mean difference of almost €2,500 in lifetime total costs between the least costly option (leuprorelin 22.5 mg) and the most expensive (goserelin). In the incremental cost-effectiveness analysis, leuprorelin 22.5 mg dominated all alternatives except buserelin, which had an incremental cost-effectiveness ratio versus leuprorelin 22.5 mg of ≈€12,000 per life-month gained.ConclusionsBased on modelling with meta-analysis of comparative survival data, leuprorelin 22.5 mg was the most cost-effective treatment of the available depot formulation LHRH agonists." @default.
• W2123238480 created "2016-06-24" @default.
• W2123238480 creator A5014024898 @default.
• W2123238480 creator A5030545731 @default.
• W2123238480 creator A5057388317 @default.
• W2123238480 creator A5058300796 @default.
• W2123238480 date "2011-01-01" @default.
• W2123238480 modified "2023-09-26" @default.
• W2123238480 title "Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy" @default.
• W2123238480 cites W105634927 @default.
• W2123238480 cites W1574558999 @default.
• W2123238480 cites W1591480142 @default.
• W2123238480 cites W1604487436 @default.
• W2123238480 cites W1966321188 @default.
• W2123238480 cites W1989586665 @default.
• W2123238480 cites W2005709546 @default.
• W2123238480 cites W2019190788 @default.
• W2123238480 cites W2023338191 @default.
• W2123238480 cites W2025053238 @default.
• W2123238480 cites W2047516139 @default.
• W2123238480 cites W2050366955 @default.
• W2123238480 cites W2051132824 @default.
• W2123238480 cites W2055051372 @default.
• W2123238480 cites W2057959903 @default.
• W2123238480 cites W2065681165 @default.
• W2123238480 cites W2066554119 @default.
• W2123238480 cites W2072407998 @default.
• W2123238480 cites W2089952228 @default.
• W2123238480 cites W2095841959 @default.
• W2123238480 cites W2103327420 @default.
• W2123238480 cites W2118523893 @default.
• W2123238480 cites W2120292596 @default.
• W2123238480 cites W2123851975 @default.
• W2123238480 cites W2150712216 @default.
• W2123238480 cites W2162460707 @default.
• W2123238480 cites W2163566079 @default.
• W2123238480 cites W2168286690 @default.
• W2123238480 cites W2168798475 @default.
• W2123238480 cites W2320883752 @default.
• W2123238480 cites W2403925725 @default.
• W2123238480 cites W4235935036 @default.
• W2123238480 cites W4321429490 @default.
• W2123238480 doi "https://doi.org/10.1016/j.jval.2010.10.023" @default.
• W2123238480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21211489" @default.
• W2123238480 hasPublicationYear "2011" @default.
• W2123238480 type Work @default.
• W2123238480 sameAs 2123238480 @default.
• W2123238480 citedByCount "12" @default.
• W2123238480 countsByYear W21232384802013 @default.
• W2123238480 countsByYear W21232384802014 @default.
• W2123238480 countsByYear W21232384802015 @default.
• W2123238480 countsByYear W21232384802016 @default.
• W2123238480 countsByYear W21232384802019 @default.
• W2123238480 countsByYear W21232384802022 @default.
• W2123238480 crossrefType "journal-article" @default.
• W2123238480 hasAuthorship W2123238480A5014024898 @default.
• W2123238480 hasAuthorship W2123238480A5030545731 @default.
• W2123238480 hasAuthorship W2123238480A5057388317 @default.
• W2123238480 hasAuthorship W2123238480A5058300796 @default.
• W2123238480 hasBestOaLocation W21232384801 @default.
• W2123238480 hasConcept C112930515 @default.
• W2123238480 hasConcept C121608353 @default.
• W2123238480 hasConcept C126322002 @default.
• W2123238480 hasConcept C126894567 @default.
• W2123238480 hasConcept C143998085 @default.
• W2123238480 hasConcept C170493617 @default.
• W2123238480 hasConcept C2777230143 @default.
• W2123238480 hasConcept C2777899217 @default.
• W2123238480 hasConcept C2778043895 @default.
• W2123238480 hasConcept C2778575703 @default.
• W2123238480 hasConcept C2778894405 @default.
• W2123238480 hasConcept C2778938600 @default.
• W2123238480 hasConcept C2779093440 @default.
• W2123238480 hasConcept C2779279991 @default.
• W2123238480 hasConcept C2779448150 @default.
• W2123238480 hasConcept C2780192828 @default.
• W2123238480 hasConcept C29456083 @default.
• W2123238480 hasConcept C3019080777 @default.
• W2123238480 hasConcept C71315377 @default.
• W2123238480 hasConcept C71924100 @default.
• W2123238480 hasConceptScore W2123238480C112930515 @default.
• W2123238480 hasConceptScore W2123238480C121608353 @default.
• W2123238480 hasConceptScore W2123238480C126322002 @default.
• W2123238480 hasConceptScore W2123238480C126894567 @default.
• W2123238480 hasConceptScore W2123238480C143998085 @default.
• W2123238480 hasConceptScore W2123238480C170493617 @default.
• W2123238480 hasConceptScore W2123238480C2777230143 @default.
• W2123238480 hasConceptScore W2123238480C2777899217 @default.
• W2123238480 hasConceptScore W2123238480C2778043895 @default.
• W2123238480 hasConceptScore W2123238480C2778575703 @default.
• W2123238480 hasConceptScore W2123238480C2778894405 @default.
• W2123238480 hasConceptScore W2123238480C2778938600 @default.
• W2123238480 hasConceptScore W2123238480C2779093440 @default.
• W2123238480 hasConceptScore W2123238480C2779279991 @default.
• W2123238480 hasConceptScore W2123238480C2779448150 @default.
• W2123238480 hasConceptScore W2123238480C2780192828 @default.
• W2123238480 hasConceptScore W2123238480C29456083 @default.
• W2123238480 hasConceptScore W2123238480C3019080777 @default.

• next